- 现金
- 692 元
- 精华
- 0
- 帖子
- 378
- 注册时间
- 2018-6-10
- 最后登录
- 2021-9-25
|
本帖最后由 pourvivre 于 2018-7-27 08:53 编辑
回复 coolzls 的帖子
乙肝确实是个穷病,这点我看法和你一致。我中学时学校检查乙肝(97年前后),我发现多数是家庭条件差,可以说幼儿时期家里吃不起肉蛋奶的孩子,家庭富裕的,如果肥胖,常常是轻度脂肪肝,没有乙肝。而且班主任歧视我的眼神,充满无知和愤怒,好像我就是一个生化污染源,这种低级文明,我至今记得,想象如今在我们那个小地方,不会有任何改变。人不能选择自己的出生环境,但是可以选择自己孩子的。
话说回来:喝酒是绝对避免的。你父亲那边,很多人概念不是很清楚,只知道这个阳性,有那个阳性,有时别人说抗体阳性,他们也许混淆了。也许本身他们就很健康,无乙肝。你千万不要碰酒。
你用药效果很不错,只要表抗原一直降低,说明身体一直有免疫反应,你有可能治愈。如果不耐药,一直吃下去,是不错的方法,起码目前没有风险。但是要加强检查,及时发现耐药。问问专家,是不是要3个月一查,你每年2次体检,也许不够,主要是为即使发现耐药。也许你用一线药物,可以加速表抗原降低,可以咨询医生用更强的药物。当然,这只是我个人想法,我不是专家,只是个病人。你坚持锻炼,这点我很赞同,我14年到16年连续2年没有跑步锻炼,体质变得很差,去年开始锻炼了,感觉身体好多了,对于健身效果,医生和研究者很难得到有利病情数据的。我觉得可能也是免疫刺激和调节的一种实际方式。只要不过劳就好。偶尔疲劳(比如熬夜)也可能刺激免疫。但是不要长期和习惯性发生就好。
最后,你说的一线药时间不久,其实不然,都有十几年历史了。
Entecavir (ETV), sold under the brand name Baraclude, is an antiviral medication used in the treatment of hepatitis B virus (HBV) infection.[1] In those with both HIV/AIDS and HBV antiretroviral medication should also be used.[1] Entecavir is taken by mouth as a tablet or solution.[1]
History
1992: SQ-34676 at Squibb as part of anti-herpes virus program[20]
1997: BMS 200475 developed at BMS pharmaceutical research institute as antiviral nucleoside analogue à Activity demonstrated against HBV, HSV-1, HCMV, VZV in cell lines & no or little activity against HIV or influenza[21]
Superior activity observed against HBV pushed research towards BMS 200475, its base analogues and its enantiomer against HBV in HepG2.2.15 cell line[21]
Comparison to other NAs, proven more selective potent inhibitor of HBV by virtue of being Guanine NA[22]
1998: Inhibition of hepadnaviral polymerases was demonstrated in vitro in comparison to a number of NAs-TP[23]
Metabolic studies showed more efficient phosphorylation to triphosphate active form[24]
3-year treatment of woodchuck model of CHB à sustained antiviral efficacy and prolonged life spans without detectable emergence of resistance[25]
Efficacy # LVD resistant HBV replication in vitro[26]
Superior activity compared to LVD in vivo for both HBeAg+ & HBeAg− patients[27][28]
Efficacy in LVD refractory CHB patients[29]
Entecavir was approved by the U.S. FDA in March 2005.
Tenofovir disoproxil, sold under the trade name Viread among others, is a medication used to treat chronic hepatitis B and to prevent and treat HIV/AIDS.[1] It is generally recommended for use with other antiretrovirals.
History
Tenofovir was initially synthesized by Antonín Holý at the Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic in Prague. The patent[15] filed by Holý in 1984 makes no mention of the potential use of the compound for the treatment of HIV infection, which had only been discovered one year earlier.
In 1985, De Clercq and Holý described the activity of PMPA against HIV in cell culture.[16] Shortly thereafter, a collaboration with the biotechnology company Gilead Sciences led to the investigation of PMPA's potential as a treatment for HIV infected patients. In 1997 researchers from Gilead and the University of California, San Francisco demonstrated that tenofovir exhibits anti-HIV effects in humans when dosed by subcutaneous injection.[17]
The initial form of tenofovir used in these studies had limited potential for widespread use because it was not absorbed when administered orally. A medicinal chemistry team at Gilead developed a modified version of tenofovir, tenofovir disoproxil.[18] This version of tenofovir is often referred to simply as "tenofovir". In this version of the drug, the two negative charges of the tenofovir phosphonic acid group are masked, thus enhancing oral absorption.
Tenofovir disoproxil was approved by the U.S. FDA on October 26, 2001, for the treatment of HIV, and on August 11, 2008, for the treatment of chronic hepatitis B.[19][20]
|
|